Cullinan Oncology
Founded 2016 · 128 employees on LinkedIn · 5 known investors
Find your way into Cullinan Oncology
Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
Investors · 5
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BJun 2020Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 2
by search overlap
Cullinan Therapeutics8 shared keywordsCullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation. The company focuses on first- or best-in-class treatments to improve outcomes for patients managing these conditions.
Seeking Alpha4 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Cullinan Oncology for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Cullinan Oncology do?
- Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
- Who are Cullinan Oncology's investors?
- Cullinan Oncology's investors include LAV, Lilly Asia Ventures, MPM BioImpact, Schooner Capital, Taiho Ventures, LLC.